nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—AURKA—melanoma	0.131	0.505	CbGaD
Doxorubicin—kidney cancer—melanoma	0.121	0.343	CtDrD
Doxorubicin—lung cancer—melanoma	0.116	0.331	CtDrD
Doxorubicin—sarcoma—melanoma	0.115	0.327	CtDrD
Doxorubicin—NOS2—melanoma	0.0616	0.236	CbGaD
Doxorubicin—ABCC6—Dactinomycin—melanoma	0.0586	0.276	CbGbCtD
Doxorubicin—CYP1B1—melanoma	0.0523	0.201	CbGaD
Doxorubicin—ABCC1—Vemurafenib—melanoma	0.026	0.123	CbGbCtD
Doxorubicin—ABCC10—Docetaxel—melanoma	0.0231	0.109	CbGbCtD
Doxorubicin—ABCG2—Vemurafenib—melanoma	0.0174	0.082	CbGbCtD
Doxorubicin—ABCC1—Dactinomycin—melanoma	0.0173	0.0814	CbGbCtD
Doxorubicin—ABCB1—melanoma	0.015	0.0577	CbGaD
Doxorubicin—CYP1B1—Docetaxel—melanoma	0.0126	0.0592	CbGbCtD
Doxorubicin—ABCG2—Dactinomycin—melanoma	0.0116	0.0545	CbGbCtD
Doxorubicin—ABCC1—Docetaxel—melanoma	0.00893	0.0421	CbGbCtD
Doxorubicin—CYP3A4—Temozolomide—melanoma	0.00687	0.0323	CbGbCtD
Doxorubicin—ABCC2—Docetaxel—melanoma	0.00661	0.0311	CbGbCtD
Doxorubicin—ABCG2—Docetaxel—melanoma	0.00597	0.0281	CbGbCtD
Doxorubicin—CYP2D6—Vemurafenib—melanoma	0.00592	0.0279	CbGbCtD
Doxorubicin—ABCB1—Dactinomycin—melanoma	0.00417	0.0197	CbGbCtD
Doxorubicin—CYP3A4—Vemurafenib—melanoma	0.00376	0.0177	CbGbCtD
Doxorubicin—ABCC6—dermis—melanoma	0.00238	0.0693	CbGeAlD
Doxorubicin—ABCB1—Docetaxel—melanoma	0.00215	0.0101	CbGbCtD
Doxorubicin—CBR3—hair follicle—melanoma	0.00134	0.0391	CbGeAlD
Doxorubicin—CYP3A4—Docetaxel—melanoma	0.00129	0.00608	CbGbCtD
Doxorubicin—NOS3—umbilical vein—melanoma	0.00128	0.0373	CbGeAlD
Doxorubicin—NOS3—hindlimb—melanoma	0.00117	0.0342	CbGeAlD
Doxorubicin—Epirubicin—AURKA—melanoma	0.00108	0.734	CrCbGaD
Doxorubicin—AKR1A1—hair follicle—melanoma	0.00104	0.0302	CbGeAlD
Doxorubicin—NOS3—appendage—melanoma	0.00101	0.0293	CbGeAlD
Doxorubicin—NOS1—endothelium—melanoma	0.000799	0.0233	CbGeAlD
Doxorubicin—NDUFS2—hair follicle—melanoma	0.00078	0.0228	CbGeAlD
Doxorubicin—NDUFS3—hair follicle—melanoma	0.000771	0.0225	CbGeAlD
Doxorubicin—NOS1—blood vessel—melanoma	0.000737	0.0215	CbGeAlD
Doxorubicin—DHCR7—hair follicle—melanoma	0.000732	0.0214	CbGeAlD
Doxorubicin—NOS3—endothelium—melanoma	0.000607	0.0177	CbGeAlD
Doxorubicin—RALBP1—hair follicle—melanoma	0.000607	0.0177	CbGeAlD
Doxorubicin—NOS3—blood vessel—melanoma	0.00056	0.0163	CbGeAlD
Doxorubicin—CBR3—mammalian vulva—melanoma	0.000532	0.0155	CbGeAlD
Doxorubicin—AKR1A1—eye—melanoma	0.000517	0.0151	CbGeAlD
Doxorubicin—AKR1A1—retina—melanoma	0.000513	0.0149	CbGeAlD
Doxorubicin—TOP2A—Paclitaxel—Docetaxel—melanoma	0.00051	1	CbGdCrCtD
Doxorubicin—AKR1A1—skin of body—melanoma	0.00045	0.0131	CbGeAlD
Doxorubicin—AKR1A1—mammalian vulva—melanoma	0.00041	0.012	CbGeAlD
Doxorubicin—NOS3—neck—melanoma	0.000401	0.0117	CbGeAlD
Doxorubicin—ABCB8—head—melanoma	0.000395	0.0115	CbGeAlD
Doxorubicin—NOS1—eye—melanoma	0.000392	0.0114	CbGeAlD
Doxorubicin—NDUFS2—eye—melanoma	0.00039	0.0114	CbGeAlD
Doxorubicin—NOS1—retina—melanoma	0.000388	0.0113	CbGeAlD
Doxorubicin—NDUFS2—retina—melanoma	0.000386	0.0113	CbGeAlD
Doxorubicin—CBR3—head—melanoma	0.00038	0.0111	CbGeAlD
Doxorubicin—DHCR7—retina—melanoma	0.000362	0.0106	CbGeAlD
Doxorubicin—ABCC6—eye—melanoma	0.000356	0.0104	CbGeAlD
Doxorubicin—ABCC6—retina—melanoma	0.000353	0.0103	CbGeAlD
Doxorubicin—AURKA—mammalian vulva—melanoma	0.000347	0.0101	CbGeAlD
Doxorubicin—NDUFS2—skin of body—melanoma	0.000339	0.00988	CbGeAlD
Doxorubicin—YWHAG—eye—melanoma	0.000335	0.00978	CbGeAlD
Doxorubicin—NDUFS3—skin of body—melanoma	0.000335	0.00976	CbGeAlD
Doxorubicin—YWHAG—retina—melanoma	0.000332	0.00969	CbGeAlD
Doxorubicin—CYP1B1—hair follicle—melanoma	0.000319	0.00929	CbGeAlD
Doxorubicin—DHCR7—skin of body—melanoma	0.000318	0.00927	CbGeAlD
Doxorubicin—NDUFS2—mammalian vulva—melanoma	0.000309	0.00901	CbGeAlD
Doxorubicin—NDUFS3—mammalian vulva—melanoma	0.000305	0.0089	CbGeAlD
Doxorubicin—Daunorubicin—CYP1B1—melanoma	0.000305	0.207	CrCbGaD
Doxorubicin—NQO1—neck—melanoma	0.000305	0.00888	CbGeAlD
Doxorubicin—RALBP1—eye—melanoma	0.000303	0.00883	CbGeAlD
Doxorubicin—RALBP1—retina—melanoma	0.0003	0.00875	CbGeAlD
Doxorubicin—AKR1A1—head—melanoma	0.000294	0.00856	CbGeAlD
Doxorubicin—DHCR7—mammalian vulva—melanoma	0.00029	0.00846	CbGeAlD
Doxorubicin—ABCC1—hair follicle—melanoma	0.000287	0.00836	CbGeAlD
Doxorubicin—CBR1—eye—melanoma	0.000283	0.00824	CbGeAlD
Doxorubicin—ABCB8—lymph node—melanoma	0.000277	0.00806	CbGeAlD
Doxorubicin—NDUFS7—head—melanoma	0.000267	0.00778	CbGeAlD
Doxorubicin—CBR3—lymph node—melanoma	0.000266	0.00776	CbGeAlD
Doxorubicin—YWHAG—mammalian vulva—melanoma	0.000266	0.00776	CbGeAlD
Doxorubicin—XDH—mammalian vulva—melanoma	0.00026	0.00757	CbGeAlD
Doxorubicin—AURKA—head—melanoma	0.000248	0.00723	CbGeAlD
Doxorubicin—CBR1—skin of body—melanoma	0.000246	0.00717	CbGeAlD
Doxorubicin—RALBP1—mammalian vulva—melanoma	0.00024	0.00701	CbGeAlD
Doxorubicin—NQO1—eye—melanoma	0.000227	0.00661	CbGeAlD
Doxorubicin—NQO1—retina—melanoma	0.000225	0.00655	CbGeAlD
Doxorubicin—CBR1—mammalian vulva—melanoma	0.000224	0.00654	CbGeAlD
Doxorubicin—NOS1—head—melanoma	0.000223	0.00649	CbGeAlD
Doxorubicin—AKR1C3—mammalian vulva—melanoma	0.000222	0.00646	CbGeAlD
Doxorubicin—NDUFS2—head—melanoma	0.000221	0.00645	CbGeAlD
Doxorubicin—NDUFS3—head—melanoma	0.000218	0.00637	CbGeAlD
Doxorubicin—DHCR7—head—melanoma	0.000208	0.00605	CbGeAlD
Doxorubicin—AKR1A1—lymph node—melanoma	0.000206	0.00599	CbGeAlD
Doxorubicin—POR—mammalian vulva—melanoma	0.000202	0.0059	CbGeAlD
Doxorubicin—ABCC6—head—melanoma	0.000202	0.0059	CbGeAlD
Doxorubicin—NQO1—skin of body—melanoma	0.000197	0.00575	CbGeAlD
Doxorubicin—YWHAG—head—melanoma	0.00019	0.00555	CbGeAlD
Doxorubicin—TOP2A—mammalian vulva—melanoma	0.000189	0.0055	CbGeAlD
Doxorubicin—NDUFS7—lymph node—melanoma	0.000187	0.00545	CbGeAlD
Doxorubicin—NQO1—mammalian vulva—melanoma	0.00018	0.00524	CbGeAlD
Doxorubicin—AURKA—lymph node—melanoma	0.000174	0.00506	CbGeAlD
Doxorubicin—RALBP1—head—melanoma	0.000172	0.00501	CbGeAlD
Doxorubicin—NOS3—head—melanoma	0.000169	0.00493	CbGeAlD
Doxorubicin—ABCC10—mammalian vulva—melanoma	0.000161	0.00468	CbGeAlD
Doxorubicin—CBR1—head—melanoma	0.000161	0.00468	CbGeAlD
Doxorubicin—CYP1B1—eye—melanoma	0.000159	0.00464	CbGeAlD
Doxorubicin—NDUFS2—lymph node—melanoma	0.000155	0.00451	CbGeAlD
Doxorubicin—NDUFS3—lymph node—melanoma	0.000153	0.00446	CbGeAlD
Doxorubicin—DHCR7—lymph node—melanoma	0.000145	0.00424	CbGeAlD
Doxorubicin—CYP1B1—skin of body—melanoma	0.000138	0.00404	CbGeAlD
Doxorubicin—YWHAG—lymph node—melanoma	0.000133	0.00389	CbGeAlD
Doxorubicin—NQO1—head—melanoma	0.000129	0.00375	CbGeAlD
Doxorubicin—RALBP1—lymph node—melanoma	0.00012	0.00351	CbGeAlD
Doxorubicin—NOS3—lymph node—melanoma	0.000118	0.00345	CbGeAlD
Doxorubicin—ABCC3—head—melanoma	0.000115	0.00337	CbGeAlD
Doxorubicin—ABCC1—mammalian vulva—melanoma	0.000114	0.00331	CbGeAlD
Doxorubicin—CBR1—lymph node—melanoma	0.000112	0.00328	CbGeAlD
Doxorubicin—AKR1C3—lymph node—melanoma	0.000111	0.00324	CbGeAlD
Doxorubicin—ABCB1—blood vessel—melanoma	0.00011	0.0032	CbGeAlD
Doxorubicin—POR—lymph node—melanoma	0.000101	0.00296	CbGeAlD
Doxorubicin—CYP2B6—skin of body—melanoma	9.51e-05	0.00277	CbGeAlD
Doxorubicin—TOP2A—lymph node—melanoma	9.45e-05	0.00275	CbGeAlD
Doxorubicin—ABCG2—mammalian vulva—melanoma	9.4e-05	0.00274	CbGeAlD
Doxorubicin—CYP1B1—head—melanoma	9.03e-05	0.00263	CbGeAlD
Doxorubicin—NQO1—lymph node—melanoma	9.01e-05	0.00263	CbGeAlD
Doxorubicin—Daunorubicin—ABCB1—melanoma	8.76e-05	0.0593	CrCbGaD
Doxorubicin—ABCC3—lymph node—melanoma	8.08e-05	0.00236	CbGeAlD
Doxorubicin—ABCC10—lymph node—melanoma	8.04e-05	0.00234	CbGeAlD
Doxorubicin—ABCC2—lymph node—melanoma	6.46e-05	0.00188	CbGeAlD
Doxorubicin—CYP1B1—lymph node—melanoma	6.33e-05	0.00184	CbGeAlD
Doxorubicin—CYP2B6—head—melanoma	6.21e-05	0.00181	CbGeAlD
Doxorubicin—ABCB1—retina—melanoma	5.79e-05	0.00169	CbGeAlD
Doxorubicin—ABCC1—lymph node—melanoma	5.69e-05	0.00166	CbGeAlD
Doxorubicin—Alopecia—Temozolomide—melanoma	4.9e-05	0.00068	CcSEcCtD
Doxorubicin—Dry skin—Docetaxel—melanoma	4.89e-05	0.000678	CcSEcCtD
Doxorubicin—Chest pain—Bleomycin—melanoma	4.87e-05	0.000677	CcSEcCtD
Doxorubicin—Myalgia—Bleomycin—melanoma	4.87e-05	0.000677	CcSEcCtD
Doxorubicin—Orthostatic hypotension—Docetaxel—melanoma	4.87e-05	0.000676	CcSEcCtD
Doxorubicin—Abdominal pain upper—Docetaxel—melanoma	4.87e-05	0.000676	CcSEcCtD
Doxorubicin—Rash—Vemurafenib—melanoma	4.86e-05	0.000675	CcSEcCtD
Doxorubicin—Mental disorder—Temozolomide—melanoma	4.86e-05	0.000675	CcSEcCtD
Doxorubicin—Dermatitis—Vemurafenib—melanoma	4.86e-05	0.000674	CcSEcCtD
Doxorubicin—Back pain—Carmustine—melanoma	4.83e-05	0.000671	CcSEcCtD
Doxorubicin—Headache—Vemurafenib—melanoma	4.83e-05	0.000671	CcSEcCtD
Doxorubicin—Malnutrition—Temozolomide—melanoma	4.83e-05	0.00067	CcSEcCtD
Doxorubicin—Erythema—Temozolomide—melanoma	4.83e-05	0.00067	CcSEcCtD
Doxorubicin—Breast disorder—Docetaxel—melanoma	4.82e-05	0.000669	CcSEcCtD
Doxorubicin—Discomfort—Bleomycin—melanoma	4.82e-05	0.000668	CcSEcCtD
Doxorubicin—Malaise—Dactinomycin—melanoma	4.81e-05	0.000668	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Docetaxel—melanoma	4.8e-05	0.000667	CcSEcCtD
Doxorubicin—Aspartate aminotransferase increased—Docetaxel—melanoma	4.8e-05	0.000667	CcSEcCtD
Doxorubicin—Leukopenia—Dactinomycin—melanoma	4.78e-05	0.000663	CcSEcCtD
Doxorubicin—Nasopharyngitis—Docetaxel—melanoma	4.77e-05	0.000662	CcSEcCtD
Doxorubicin—Dysgeusia—Temozolomide—melanoma	4.73e-05	0.000656	CcSEcCtD
Doxorubicin—Confusional state—Bleomycin—melanoma	4.71e-05	0.000654	CcSEcCtD
Doxorubicin—ABCG2—lymph node—melanoma	4.71e-05	0.00137	CbGeAlD
Doxorubicin—Vision blurred—Carmustine—melanoma	4.71e-05	0.000654	CcSEcCtD
Doxorubicin—Alanine aminotransferase increased—Docetaxel—melanoma	4.7e-05	0.000653	CcSEcCtD
Doxorubicin—Anaphylactic shock—Bleomycin—melanoma	4.67e-05	0.000649	CcSEcCtD
Doxorubicin—Oedema—Bleomycin—melanoma	4.67e-05	0.000649	CcSEcCtD
Doxorubicin—Back pain—Temozolomide—melanoma	4.67e-05	0.000648	CcSEcCtD
Doxorubicin—Infection—Bleomycin—melanoma	4.64e-05	0.000644	CcSEcCtD
Doxorubicin—ABCB1—mammalian vulva—melanoma	4.64e-05	0.00135	CbGeAlD
Doxorubicin—Anaemia—Carmustine—melanoma	4.62e-05	0.000641	CcSEcCtD
Doxorubicin—CYP2D6—head—melanoma	4.61e-05	0.00134	CbGeAlD
Doxorubicin—Dysphagia—Docetaxel—melanoma	4.61e-05	0.00064	CcSEcCtD
Doxorubicin—Agitation—Carmustine—melanoma	4.59e-05	0.000637	CcSEcCtD
Doxorubicin—Nausea—Vemurafenib—melanoma	4.58e-05	0.000636	CcSEcCtD
Doxorubicin—Thrombocytopenia—Bleomycin—melanoma	4.57e-05	0.000635	CcSEcCtD
Doxorubicin—Vision blurred—Temozolomide—melanoma	4.55e-05	0.000632	CcSEcCtD
Doxorubicin—Myalgia—Dactinomycin—melanoma	4.55e-05	0.000631	CcSEcCtD
Doxorubicin—Discomfort—Dactinomycin—melanoma	4.49e-05	0.000623	CcSEcCtD
Doxorubicin—Angina pectoris—Docetaxel—melanoma	4.49e-05	0.000623	CcSEcCtD
Doxorubicin—Ill-defined disorder—Temozolomide—melanoma	4.48e-05	0.000622	CcSEcCtD
Doxorubicin—Leukopenia—Carmustine—melanoma	4.47e-05	0.000621	CcSEcCtD
Doxorubicin—Anaemia—Temozolomide—melanoma	4.46e-05	0.00062	CcSEcCtD
Doxorubicin—Anorexia—Bleomycin—melanoma	4.45e-05	0.000618	CcSEcCtD
Doxorubicin—Agitation—Temozolomide—melanoma	4.44e-05	0.000616	CcSEcCtD
Doxorubicin—Pancytopenia—Docetaxel—melanoma	4.38e-05	0.000608	CcSEcCtD
Doxorubicin—Hypotension—Bleomycin—melanoma	4.37e-05	0.000606	CcSEcCtD
Doxorubicin—Oedema—Dactinomycin—melanoma	4.36e-05	0.000605	CcSEcCtD
Doxorubicin—Malaise—Temozolomide—melanoma	4.35e-05	0.000604	CcSEcCtD
Doxorubicin—Vertigo—Temozolomide—melanoma	4.34e-05	0.000602	CcSEcCtD
Doxorubicin—Convulsion—Carmustine—melanoma	4.33e-05	0.000601	CcSEcCtD
Doxorubicin—Infection—Dactinomycin—melanoma	4.33e-05	0.000601	CcSEcCtD
Doxorubicin—Leukopenia—Temozolomide—melanoma	4.32e-05	0.0006	CcSEcCtD
Doxorubicin—Hypertension—Carmustine—melanoma	4.31e-05	0.000599	CcSEcCtD
Doxorubicin—Neutropenia—Docetaxel—melanoma	4.31e-05	0.000598	CcSEcCtD
Doxorubicin—Palpitations—Temozolomide—melanoma	4.27e-05	0.000592	CcSEcCtD
Doxorubicin—Thrombocytopenia—Dactinomycin—melanoma	4.27e-05	0.000592	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Bleomycin—melanoma	4.26e-05	0.000591	CcSEcCtD
Doxorubicin—Chest pain—Carmustine—melanoma	4.25e-05	0.000591	CcSEcCtD
Doxorubicin—Myalgia—Carmustine—melanoma	4.25e-05	0.000591	CcSEcCtD
Doxorubicin—Anxiety—Carmustine—melanoma	4.24e-05	0.000588	CcSEcCtD
Doxorubicin—Cough—Temozolomide—melanoma	4.21e-05	0.000585	CcSEcCtD
Doxorubicin—Paraesthesia—Bleomycin—melanoma	4.2e-05	0.000582	CcSEcCtD
Doxorubicin—Weight increased—Docetaxel—melanoma	4.19e-05	0.000582	CcSEcCtD
Doxorubicin—Convulsion—Temozolomide—melanoma	4.18e-05	0.000581	CcSEcCtD
Doxorubicin—Weight decreased—Docetaxel—melanoma	4.17e-05	0.000579	CcSEcCtD
Doxorubicin—Hypertension—Temozolomide—melanoma	4.17e-05	0.000579	CcSEcCtD
Doxorubicin—Dyspnoea—Bleomycin—melanoma	4.17e-05	0.000578	CcSEcCtD
Doxorubicin—Anorexia—Dactinomycin—melanoma	4.15e-05	0.000577	CcSEcCtD
Doxorubicin—Pneumonia—Docetaxel—melanoma	4.13e-05	0.000574	CcSEcCtD
Doxorubicin—Confusional state—Carmustine—melanoma	4.11e-05	0.000571	CcSEcCtD
Doxorubicin—Arthralgia—Temozolomide—melanoma	4.11e-05	0.000571	CcSEcCtD
Doxorubicin—Myalgia—Temozolomide—melanoma	4.11e-05	0.000571	CcSEcCtD
Doxorubicin—Infestation NOS—Docetaxel—melanoma	4.11e-05	0.00057	CcSEcCtD
Doxorubicin—Infestation—Docetaxel—melanoma	4.11e-05	0.00057	CcSEcCtD
Doxorubicin—Anxiety—Temozolomide—melanoma	4.1e-05	0.000569	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	4.08e-05	0.000567	CcSEcCtD
Doxorubicin—Oedema—Carmustine—melanoma	4.08e-05	0.000566	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Docetaxel—melanoma	4.07e-05	0.000566	CcSEcCtD
Doxorubicin—Discomfort—Temozolomide—melanoma	4.06e-05	0.000564	CcSEcCtD
Doxorubicin—Decreased appetite—Bleomycin—melanoma	4.06e-05	0.000564	CcSEcCtD
Doxorubicin—Infection—Carmustine—melanoma	4.05e-05	0.000562	CcSEcCtD
Doxorubicin—Renal failure—Docetaxel—melanoma	4.04e-05	0.000561	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Docetaxel—melanoma	4.03e-05	0.000559	CcSEcCtD
Doxorubicin—Dry mouth—Temozolomide—melanoma	4.02e-05	0.000558	CcSEcCtD
Doxorubicin—Stomatitis—Docetaxel—melanoma	4.01e-05	0.000556	CcSEcCtD
Doxorubicin—Jaundice—Docetaxel—melanoma	4.01e-05	0.000556	CcSEcCtD
Doxorubicin—Pain—Bleomycin—melanoma	4e-05	0.000555	CcSEcCtD
Doxorubicin—Conjunctivitis—Docetaxel—melanoma	3.99e-05	0.000554	CcSEcCtD
Doxorubicin—Thrombocytopenia—Carmustine—melanoma	3.99e-05	0.000554	CcSEcCtD
Doxorubicin—Tachycardia—Carmustine—melanoma	3.98e-05	0.000552	CcSEcCtD
Doxorubicin—Confusional state—Temozolomide—melanoma	3.97e-05	0.000552	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Dactinomycin—melanoma	3.97e-05	0.000551	CcSEcCtD
Doxorubicin—Anaphylactic shock—Temozolomide—melanoma	3.94e-05	0.000547	CcSEcCtD
Doxorubicin—Oedema—Temozolomide—melanoma	3.94e-05	0.000547	CcSEcCtD
Doxorubicin—Infection—Temozolomide—melanoma	3.92e-05	0.000543	CcSEcCtD
Doxorubicin—Anorexia—Carmustine—melanoma	3.89e-05	0.00054	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Docetaxel—melanoma	3.89e-05	0.000539	CcSEcCtD
Doxorubicin—Epistaxis—Docetaxel—melanoma	3.88e-05	0.000538	CcSEcCtD
Doxorubicin—Nervous system disorder—Temozolomide—melanoma	3.87e-05	0.000536	CcSEcCtD
Doxorubicin—Thrombocytopenia—Temozolomide—melanoma	3.86e-05	0.000536	CcSEcCtD
Doxorubicin—Feeling abnormal—Bleomycin—melanoma	3.85e-05	0.000534	CcSEcCtD
Doxorubicin—Agranulocytosis—Docetaxel—melanoma	3.84e-05	0.000532	CcSEcCtD
Doxorubicin—Skin disorder—Temozolomide—melanoma	3.83e-05	0.000531	CcSEcCtD
Doxorubicin—Hypotension—Carmustine—melanoma	3.81e-05	0.000529	CcSEcCtD
Doxorubicin—Hyperhidrosis—Temozolomide—melanoma	3.81e-05	0.000529	CcSEcCtD
Doxorubicin—Decreased appetite—Dactinomycin—melanoma	3.79e-05	0.000526	CcSEcCtD
Doxorubicin—Fatigue—Dactinomycin—melanoma	3.76e-05	0.000521	CcSEcCtD
Doxorubicin—Anorexia—Temozolomide—melanoma	3.76e-05	0.000521	CcSEcCtD
Doxorubicin—Pain—Dactinomycin—melanoma	3.73e-05	0.000517	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Carmustine—melanoma	3.72e-05	0.000516	CcSEcCtD
Doxorubicin—Urticaria—Bleomycin—melanoma	3.71e-05	0.000515	CcSEcCtD
Doxorubicin—Haemoglobin—Docetaxel—melanoma	3.71e-05	0.000515	CcSEcCtD
Doxorubicin—Rhinitis—Docetaxel—melanoma	3.7e-05	0.000513	CcSEcCtD
Doxorubicin—Body temperature increased—Bleomycin—melanoma	3.69e-05	0.000513	CcSEcCtD
Doxorubicin—Haemorrhage—Docetaxel—melanoma	3.69e-05	0.000512	CcSEcCtD
Doxorubicin—Hepatitis—Docetaxel—melanoma	3.69e-05	0.000512	CcSEcCtD
Doxorubicin—Insomnia—Carmustine—melanoma	3.69e-05	0.000512	CcSEcCtD
Doxorubicin—Hypoaesthesia—Docetaxel—melanoma	3.67e-05	0.000509	CcSEcCtD
Doxorubicin—Paraesthesia—Carmustine—melanoma	3.66e-05	0.000508	CcSEcCtD
Doxorubicin—Pharyngitis—Docetaxel—melanoma	3.66e-05	0.000508	CcSEcCtD
Doxorubicin—Urinary tract disorder—Docetaxel—melanoma	3.64e-05	0.000506	CcSEcCtD
Doxorubicin—Dyspnoea—Carmustine—melanoma	3.64e-05	0.000505	CcSEcCtD
Doxorubicin—Oedema peripheral—Docetaxel—melanoma	3.63e-05	0.000504	CcSEcCtD
Doxorubicin—Somnolence—Carmustine—melanoma	3.63e-05	0.000503	CcSEcCtD
Doxorubicin—Connective tissue disorder—Docetaxel—melanoma	3.63e-05	0.000503	CcSEcCtD
Doxorubicin—Urethral disorder—Docetaxel—melanoma	3.62e-05	0.000502	CcSEcCtD
Doxorubicin—Feeling abnormal—Dactinomycin—melanoma	3.59e-05	0.000498	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Temozolomide—melanoma	3.59e-05	0.000498	CcSEcCtD
Doxorubicin—Insomnia—Temozolomide—melanoma	3.56e-05	0.000495	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Dactinomycin—melanoma	3.56e-05	0.000495	CcSEcCtD
Doxorubicin—Visual impairment—Docetaxel—melanoma	3.56e-05	0.000493	CcSEcCtD
Doxorubicin—Decreased appetite—Carmustine—melanoma	3.55e-05	0.000492	CcSEcCtD
Doxorubicin—Paraesthesia—Temozolomide—melanoma	3.54e-05	0.000491	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Carmustine—melanoma	3.52e-05	0.000489	CcSEcCtD
Doxorubicin—Dyspnoea—Temozolomide—melanoma	3.51e-05	0.000488	CcSEcCtD
Doxorubicin—Somnolence—Temozolomide—melanoma	3.5e-05	0.000486	CcSEcCtD
Doxorubicin—Erythema multiforme—Docetaxel—melanoma	3.49e-05	0.000484	CcSEcCtD
Doxorubicin—Pain—Carmustine—melanoma	3.49e-05	0.000484	CcSEcCtD
Doxorubicin—Constipation—Carmustine—melanoma	3.49e-05	0.000484	CcSEcCtD
Doxorubicin—Dyspepsia—Temozolomide—melanoma	3.47e-05	0.000482	CcSEcCtD
Doxorubicin—Eye disorder—Docetaxel—melanoma	3.45e-05	0.000479	CcSEcCtD
Doxorubicin—Abdominal pain—Dactinomycin—melanoma	3.44e-05	0.000478	CcSEcCtD
Doxorubicin—Body temperature increased—Dactinomycin—melanoma	3.44e-05	0.000478	CcSEcCtD
Doxorubicin—Hypersensitivity—Bleomycin—melanoma	3.44e-05	0.000478	CcSEcCtD
Doxorubicin—Decreased appetite—Temozolomide—melanoma	3.43e-05	0.000476	CcSEcCtD
Doxorubicin—Cardiac disorder—Docetaxel—melanoma	3.42e-05	0.000475	CcSEcCtD
Doxorubicin—Flushing—Docetaxel—melanoma	3.42e-05	0.000475	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Temozolomide—melanoma	3.4e-05	0.000472	CcSEcCtD
Doxorubicin—Fatigue—Temozolomide—melanoma	3.4e-05	0.000472	CcSEcCtD
Doxorubicin—Constipation—Temozolomide—melanoma	3.37e-05	0.000468	CcSEcCtD
Doxorubicin—Pain—Temozolomide—melanoma	3.37e-05	0.000468	CcSEcCtD
Doxorubicin—Feeling abnormal—Carmustine—melanoma	3.36e-05	0.000466	CcSEcCtD
Doxorubicin—Asthenia—Bleomycin—melanoma	3.35e-05	0.000465	CcSEcCtD
Doxorubicin—Angiopathy—Docetaxel—melanoma	3.35e-05	0.000465	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Carmustine—melanoma	3.34e-05	0.000463	CcSEcCtD
Doxorubicin—Immune system disorder—Docetaxel—melanoma	3.33e-05	0.000463	CcSEcCtD
Doxorubicin—Mediastinal disorder—Docetaxel—melanoma	3.32e-05	0.000461	CcSEcCtD
Doxorubicin—ABCB1—head—melanoma	3.32e-05	0.000967	CbGeAlD
Doxorubicin—Chills—Docetaxel—melanoma	3.31e-05	0.000459	CcSEcCtD
Doxorubicin—Pruritus—Bleomycin—melanoma	3.31e-05	0.000459	CcSEcCtD
Doxorubicin—Arrhythmia—Docetaxel—melanoma	3.3e-05	0.000457	CcSEcCtD
Doxorubicin—Alopecia—Docetaxel—melanoma	3.26e-05	0.000452	CcSEcCtD
Doxorubicin—Feeling abnormal—Temozolomide—melanoma	3.25e-05	0.000451	CcSEcCtD
Doxorubicin—Mental disorder—Docetaxel—melanoma	3.23e-05	0.000449	CcSEcCtD
Doxorubicin—Abdominal pain—Carmustine—melanoma	3.22e-05	0.000448	CcSEcCtD
Doxorubicin—Body temperature increased—Carmustine—melanoma	3.22e-05	0.000448	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Temozolomide—melanoma	3.22e-05	0.000447	CcSEcCtD
Doxorubicin—Malnutrition—Docetaxel—melanoma	3.21e-05	0.000446	CcSEcCtD
Doxorubicin—Erythema—Docetaxel—melanoma	3.21e-05	0.000446	CcSEcCtD
Doxorubicin—Hypersensitivity—Dactinomycin—melanoma	3.21e-05	0.000446	CcSEcCtD
Doxorubicin—Dysgeusia—Docetaxel—melanoma	3.14e-05	0.000437	CcSEcCtD
Doxorubicin—Urticaria—Temozolomide—melanoma	3.13e-05	0.000435	CcSEcCtD
Doxorubicin—Asthenia—Dactinomycin—melanoma	3.13e-05	0.000434	CcSEcCtD
Doxorubicin—Body temperature increased—Temozolomide—melanoma	3.12e-05	0.000432	CcSEcCtD
Doxorubicin—Abdominal pain—Temozolomide—melanoma	3.12e-05	0.000432	CcSEcCtD
Doxorubicin—Back pain—Docetaxel—melanoma	3.11e-05	0.000431	CcSEcCtD
Doxorubicin—Muscle spasms—Docetaxel—melanoma	3.09e-05	0.000429	CcSEcCtD
Doxorubicin—Hypersensitivity—Carmustine—melanoma	3e-05	0.000417	CcSEcCtD
Doxorubicin—Diarrhoea—Dactinomycin—melanoma	2.98e-05	0.000414	CcSEcCtD
Doxorubicin—Vomiting—Bleomycin—melanoma	2.97e-05	0.000412	CcSEcCtD
Doxorubicin—Anaemia—Docetaxel—melanoma	2.97e-05	0.000412	CcSEcCtD
Doxorubicin—Rash—Bleomycin—melanoma	2.95e-05	0.000409	CcSEcCtD
Doxorubicin—Dermatitis—Bleomycin—melanoma	2.94e-05	0.000409	CcSEcCtD
Doxorubicin—Asthenia—Carmustine—melanoma	2.93e-05	0.000406	CcSEcCtD
Doxorubicin—Hypersensitivity—Temozolomide—melanoma	2.9e-05	0.000403	CcSEcCtD
Doxorubicin—Syncope—Docetaxel—melanoma	2.88e-05	0.0004	CcSEcCtD
Doxorubicin—Leukopenia—Docetaxel—melanoma	2.87e-05	0.000399	CcSEcCtD
Doxorubicin—Palpitations—Docetaxel—melanoma	2.84e-05	0.000394	CcSEcCtD
Doxorubicin—Asthenia—Temozolomide—melanoma	2.83e-05	0.000392	CcSEcCtD
Doxorubicin—Loss of consciousness—Docetaxel—melanoma	2.82e-05	0.000392	CcSEcCtD
Doxorubicin—Cough—Docetaxel—melanoma	2.8e-05	0.000389	CcSEcCtD
Doxorubicin—Diarrhoea—Carmustine—melanoma	2.79e-05	0.000387	CcSEcCtD
Doxorubicin—Pruritus—Temozolomide—melanoma	2.79e-05	0.000387	CcSEcCtD
Doxorubicin—Convulsion—Docetaxel—melanoma	2.78e-05	0.000386	CcSEcCtD
Doxorubicin—Nausea—Bleomycin—melanoma	2.78e-05	0.000385	CcSEcCtD
Doxorubicin—Hypertension—Docetaxel—melanoma	2.77e-05	0.000385	CcSEcCtD
Doxorubicin—Vomiting—Dactinomycin—melanoma	2.77e-05	0.000385	CcSEcCtD
Doxorubicin—Rash—Dactinomycin—melanoma	2.75e-05	0.000381	CcSEcCtD
Doxorubicin—Arthralgia—Docetaxel—melanoma	2.73e-05	0.000379	CcSEcCtD
Doxorubicin—Myalgia—Docetaxel—melanoma	2.73e-05	0.000379	CcSEcCtD
Doxorubicin—Chest pain—Docetaxel—melanoma	2.73e-05	0.000379	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	2.72e-05	0.000377	CcSEcCtD
Doxorubicin—Dizziness—Carmustine—melanoma	2.7e-05	0.000374	CcSEcCtD
Doxorubicin—Diarrhoea—Temozolomide—melanoma	2.7e-05	0.000374	CcSEcCtD
Doxorubicin—Dry mouth—Docetaxel—melanoma	2.67e-05	0.000371	CcSEcCtD
Doxorubicin—Confusional state—Docetaxel—melanoma	2.64e-05	0.000367	CcSEcCtD
Doxorubicin—Anaphylactic shock—Docetaxel—melanoma	2.62e-05	0.000364	CcSEcCtD
Doxorubicin—Oedema—Docetaxel—melanoma	2.62e-05	0.000364	CcSEcCtD
Doxorubicin—Dizziness—Temozolomide—melanoma	2.61e-05	0.000362	CcSEcCtD
Doxorubicin—Infection—Docetaxel—melanoma	2.6e-05	0.000361	CcSEcCtD
Doxorubicin—Vomiting—Carmustine—melanoma	2.59e-05	0.00036	CcSEcCtD
Doxorubicin—Nausea—Dactinomycin—melanoma	2.59e-05	0.000359	CcSEcCtD
Doxorubicin—Shock—Docetaxel—melanoma	2.58e-05	0.000358	CcSEcCtD
Doxorubicin—Rash—Carmustine—melanoma	2.57e-05	0.000357	CcSEcCtD
Doxorubicin—Nervous system disorder—Docetaxel—melanoma	2.57e-05	0.000357	CcSEcCtD
Doxorubicin—Dermatitis—Carmustine—melanoma	2.57e-05	0.000357	CcSEcCtD
Doxorubicin—Thrombocytopenia—Docetaxel—melanoma	2.57e-05	0.000356	CcSEcCtD
Doxorubicin—Tachycardia—Docetaxel—melanoma	2.56e-05	0.000355	CcSEcCtD
Doxorubicin—Headache—Carmustine—melanoma	2.56e-05	0.000355	CcSEcCtD
Doxorubicin—Skin disorder—Docetaxel—melanoma	2.55e-05	0.000353	CcSEcCtD
Doxorubicin—Vomiting—Temozolomide—melanoma	2.51e-05	0.000348	CcSEcCtD
Doxorubicin—Anorexia—Docetaxel—melanoma	2.5e-05	0.000347	CcSEcCtD
Doxorubicin—Rash—Temozolomide—melanoma	2.49e-05	0.000345	CcSEcCtD
Doxorubicin—Dermatitis—Temozolomide—melanoma	2.48e-05	0.000345	CcSEcCtD
Doxorubicin—Headache—Temozolomide—melanoma	2.47e-05	0.000343	CcSEcCtD
Doxorubicin—Hypotension—Docetaxel—melanoma	2.45e-05	0.00034	CcSEcCtD
Doxorubicin—Nausea—Carmustine—melanoma	2.42e-05	0.000336	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Docetaxel—melanoma	2.39e-05	0.000331	CcSEcCtD
Doxorubicin—Insomnia—Docetaxel—melanoma	2.37e-05	0.000329	CcSEcCtD
Doxorubicin—Paraesthesia—Docetaxel—melanoma	2.35e-05	0.000327	CcSEcCtD
Doxorubicin—Nausea—Temozolomide—melanoma	2.34e-05	0.000325	CcSEcCtD
Doxorubicin—Dyspnoea—Docetaxel—melanoma	2.34e-05	0.000324	CcSEcCtD
Doxorubicin—Somnolence—Docetaxel—melanoma	2.33e-05	0.000323	CcSEcCtD
Doxorubicin—ABCB1—lymph node—melanoma	2.32e-05	0.000677	CbGeAlD
Doxorubicin—Dyspepsia—Docetaxel—melanoma	2.31e-05	0.00032	CcSEcCtD
Doxorubicin—Decreased appetite—Docetaxel—melanoma	2.28e-05	0.000316	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Docetaxel—melanoma	2.26e-05	0.000314	CcSEcCtD
Doxorubicin—Fatigue—Docetaxel—melanoma	2.26e-05	0.000314	CcSEcCtD
Doxorubicin—Constipation—Docetaxel—melanoma	2.24e-05	0.000311	CcSEcCtD
Doxorubicin—Pain—Docetaxel—melanoma	2.24e-05	0.000311	CcSEcCtD
Doxorubicin—Feeling abnormal—Docetaxel—melanoma	2.16e-05	0.0003	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Docetaxel—melanoma	2.14e-05	0.000297	CcSEcCtD
Doxorubicin—Abdominal pain—Docetaxel—melanoma	2.07e-05	0.000288	CcSEcCtD
Doxorubicin—Body temperature increased—Docetaxel—melanoma	2.07e-05	0.000288	CcSEcCtD
Doxorubicin—Hypersensitivity—Docetaxel—melanoma	1.93e-05	0.000268	CcSEcCtD
Doxorubicin—Asthenia—Docetaxel—melanoma	1.88e-05	0.000261	CcSEcCtD
Doxorubicin—Pruritus—Docetaxel—melanoma	1.85e-05	0.000257	CcSEcCtD
Doxorubicin—Diarrhoea—Docetaxel—melanoma	1.79e-05	0.000249	CcSEcCtD
Doxorubicin—Dizziness—Docetaxel—melanoma	1.73e-05	0.000241	CcSEcCtD
Doxorubicin—Vomiting—Docetaxel—melanoma	1.67e-05	0.000231	CcSEcCtD
Doxorubicin—Rash—Docetaxel—melanoma	1.65e-05	0.000229	CcSEcCtD
Doxorubicin—Dermatitis—Docetaxel—melanoma	1.65e-05	0.000229	CcSEcCtD
Doxorubicin—Headache—Docetaxel—melanoma	1.64e-05	0.000228	CcSEcCtD
Doxorubicin—Nausea—Docetaxel—melanoma	1.56e-05	0.000216	CcSEcCtD
Doxorubicin—NOS3—Signaling Pathways—MAP2K1—melanoma	1.37e-06	2.06e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL6—melanoma	1.37e-06	2.05e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CD—melanoma	1.36e-06	2.04e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CD80—melanoma	1.35e-06	2.03e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL8—melanoma	1.35e-06	2.03e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTEN—melanoma	1.35e-06	2.03e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	1.35e-06	2.03e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—APC—melanoma	1.35e-06	2.02e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KIT—melanoma	1.35e-06	2.02e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—FASN—melanoma	1.35e-06	2.02e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PLA2G6—melanoma	1.34e-06	2.01e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGF—melanoma	1.33e-06	2e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—KRAS—melanoma	1.33e-06	2e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PIK3CA—melanoma	1.33e-06	2e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—SLC5A5—melanoma	1.33e-06	1.99e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CD—melanoma	1.32e-06	1.98e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CDKN1B—melanoma	1.32e-06	1.98e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SLC6A11—melanoma	1.32e-06	1.98e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIP4K2A—melanoma	1.32e-06	1.98e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—STAT3—melanoma	1.31e-06	1.97e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—NRAS—melanoma	1.31e-06	1.96e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	1.31e-06	1.96e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—ALB—melanoma	1.31e-06	1.96e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—FGF2—melanoma	1.31e-06	1.96e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CASP3—melanoma	1.29e-06	1.94e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL2—melanoma	1.29e-06	1.94e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—MTAP—melanoma	1.28e-06	1.92e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—GNAQ—melanoma	1.28e-06	1.92e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CD44—melanoma	1.28e-06	1.92e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—VCAN—melanoma	1.28e-06	1.91e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PRKCA—melanoma	1.27e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—BRAF—melanoma	1.27e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CD—melanoma	1.27e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—AKT1—melanoma	1.26e-06	1.9e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ERCC2—melanoma	1.26e-06	1.89e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCND1—melanoma	1.26e-06	1.89e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MAPK3—melanoma	1.25e-06	1.88e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—ALB—melanoma	1.25e-06	1.88e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CTNNB1—melanoma	1.25e-06	1.87e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—HRAS—melanoma	1.23e-06	1.85e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTEN—melanoma	1.23e-06	1.84e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP1B1—melanoma	1.23e-06	1.84e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PIK3CA—melanoma	1.22e-06	1.84e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MMP9—melanoma	1.22e-06	1.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MDM2—melanoma	1.22e-06	1.83e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MYC—melanoma	1.22e-06	1.83e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CDKN1A—melanoma	1.22e-06	1.83e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PTEN—melanoma	1.22e-06	1.82e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NFKB1—melanoma	1.21e-06	1.81e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ERBB2—melanoma	1.2e-06	1.81e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—VCAN—melanoma	1.2e-06	1.8e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MAP2K1—melanoma	1.19e-06	1.79e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MAPK1—melanoma	1.19e-06	1.79e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EGFR—melanoma	1.19e-06	1.79e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CB—melanoma	1.19e-06	1.78e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CD—melanoma	1.19e-06	1.78e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.19e-06	1.78e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—IL6—melanoma	1.18e-06	1.77e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CB—melanoma	1.15e-06	1.73e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	1.15e-06	1.72e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—LUM—melanoma	1.14e-06	1.71e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PHGDH—melanoma	1.14e-06	1.71e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTGS2—melanoma	1.14e-06	1.71e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL8—melanoma	1.14e-06	1.71e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—FGF2—melanoma	1.14e-06	1.7e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—HRAS—melanoma	1.13e-06	1.7e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CG—melanoma	1.13e-06	1.7e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—KRAS—melanoma	1.13e-06	1.69e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—HPSE—melanoma	1.12e-06	1.68e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CDKN1B—melanoma	1.12e-06	1.67e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CB—melanoma	1.11e-06	1.66e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	1.1e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CUBN—melanoma	1.1e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—melanoma	1.1e-06	1.65e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTGS2—melanoma	1.1e-06	1.64e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CG—melanoma	1.09e-06	1.64e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CASP3—melanoma	1.09e-06	1.64e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL2—melanoma	1.09e-06	1.64e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PPARG—melanoma	1.09e-06	1.64e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—AKT1—melanoma	1.09e-06	1.63e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—STAT3—melanoma	1.09e-06	1.63e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NRAS—melanoma	1.08e-06	1.63e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—IL6—melanoma	1.08e-06	1.63e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP17A1—melanoma	1.08e-06	1.61e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCND1—melanoma	1.06e-06	1.6e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MDM2—melanoma	1.06e-06	1.59e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PIK3CA—melanoma	1.06e-06	1.59e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SDHD—melanoma	1.06e-06	1.59e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CSPG4—melanoma	1.06e-06	1.59e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—BSG—melanoma	1.06e-06	1.59e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PPARG—melanoma	1.06e-06	1.58e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CTNNB1—melanoma	1.05e-06	1.58e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ERBB2—melanoma	1.05e-06	1.57e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MAPK3—melanoma	1.04e-06	1.56e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PIK3CA—melanoma	1.03e-06	1.55e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CB—melanoma	1.03e-06	1.55e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MMP9—melanoma	1.03e-06	1.55e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CD4—melanoma	1.03e-06	1.55e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CDKN1A—melanoma	1.03e-06	1.54e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GPAM—melanoma	1.03e-06	1.54e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PTEN—melanoma	1.03e-06	1.54e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PIK3CA—melanoma	1.03e-06	1.54e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTGS2—melanoma	1.02e-06	1.54e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NFKB1—melanoma	1.02e-06	1.53e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GNA11—melanoma	1.02e-06	1.52e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP17A1—melanoma	1.01e-06	1.52e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ABCB1—melanoma	1.01e-06	1.52e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MYC—melanoma	1.01e-06	1.51e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—AKT1—melanoma	1e-06	1.5e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	9.96e-07	1.49e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTEN—melanoma	9.96e-07	1.49e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—FASN—melanoma	9.95e-07	1.49e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CG—melanoma	9.95e-07	1.49e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CD—melanoma	9.94e-07	1.49e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MAPK1—melanoma	9.88e-07	1.48e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EGFR—melanoma	9.88e-07	1.48e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ALB—melanoma	9.81e-07	1.47e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SLC5A5—melanoma	9.78e-07	1.47e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CDKN1B—melanoma	9.71e-07	1.46e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CD—melanoma	9.61e-07	1.44e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PPARG—melanoma	9.6e-07	1.44e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GNA11—melanoma	9.58e-07	1.44e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HRAS—melanoma	9.57e-07	1.44e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTEN—melanoma	9.55e-07	1.43e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PIK3CA—melanoma	9.53e-07	1.43e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ALB—melanoma	9.49e-07	1.42e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—GNAQ—melanoma	9.45e-07	1.42e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CD44—melanoma	9.45e-07	1.42e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—FASN—melanoma	9.37e-07	1.41e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KRAS—melanoma	9.33e-07	1.4e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PRKCA—melanoma	9.31e-07	1.4e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—melanoma	9.28e-07	1.39e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ERCC2—melanoma	9.23e-07	1.38e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SLC5A5—melanoma	9.22e-07	1.38e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—STAT3—melanoma	9.18e-07	1.38e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CTNNB1—melanoma	9.17e-07	1.37e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NRAS—melanoma	9.16e-07	1.37e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—IL6—melanoma	9.16e-07	1.37e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP1B1—melanoma	9.06e-07	1.36e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CDKN1A—melanoma	8.96e-07	1.34e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTEN—melanoma	8.94e-07	1.34e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—GNAQ—melanoma	8.9e-07	1.34e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CD44—melanoma	8.9e-07	1.34e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MAPK3—melanoma	8.78e-07	1.32e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PLA2G6—melanoma	8.75e-07	1.31e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CD—melanoma	8.74e-07	1.31e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—AKT1—melanoma	8.68e-07	1.3e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CA—melanoma	8.66e-07	1.3e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CB—melanoma	8.66e-07	1.3e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ALB—melanoma	8.63e-07	1.29e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTGS2—melanoma	8.58e-07	1.29e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CA—melanoma	8.57e-07	1.29e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP1B1—melanoma	8.54e-07	1.28e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MYC—melanoma	8.53e-07	1.28e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—AKT1—melanoma	8.45e-07	1.27e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—AKT1—melanoma	8.38e-07	1.26e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CB—melanoma	8.38e-07	1.26e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MAPK1—melanoma	8.35e-07	1.25e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EGFR—melanoma	8.35e-07	1.25e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTGS2—melanoma	8.3e-07	1.24e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—melanoma	8.3e-07	1.24e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—STAT3—melanoma	7.99e-07	1.2e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NRAS—melanoma	7.97e-07	1.2e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—HRAS—melanoma	7.93e-07	1.19e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KRAS—melanoma	7.89e-07	1.18e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—VCAN—melanoma	7.86e-07	1.18e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—AKT1—melanoma	7.79e-07	1.17e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MAPK3—melanoma	7.64e-07	1.15e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CB—melanoma	7.62e-07	1.14e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL6—melanoma	7.59e-07	1.14e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTGS2—melanoma	7.55e-07	1.13e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTEN—melanoma	7.48e-07	1.12e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MYC—melanoma	7.43e-07	1.11e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CG—melanoma	7.29e-07	1.09e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MAPK1—melanoma	7.27e-07	1.09e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGFR—melanoma	7.26e-07	1.09e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CA—melanoma	7.25e-07	1.09e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTEN—melanoma	7.24e-07	1.09e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—AKT1—melanoma	7.08e-07	1.06e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PPARG—melanoma	7.04e-07	1.06e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ABCB1—melanoma	7.03e-07	1.05e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CA—melanoma	7.03e-07	1.05e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—melanoma	7.01e-07	1.05e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—AKT1—melanoma	7e-07	1.05e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PRKCA—melanoma	6.87e-07	1.03e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KRAS—melanoma	6.86e-07	1.03e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ERCC2—melanoma	6.81e-07	1.02e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CA—melanoma	6.74e-07	1.01e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HRAS—melanoma	6.7e-07	1.01e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP17A1—melanoma	6.63e-07	9.94e-06	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTEN—melanoma	6.59e-07	9.88e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PRKCA—melanoma	6.47e-07	9.7e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ERCC2—melanoma	6.42e-07	9.62e-06	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL6—melanoma	6.42e-07	9.62e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CD—melanoma	6.41e-07	9.61e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ALB—melanoma	6.33e-07	9.49e-06	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CA—melanoma	6.3e-07	9.45e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GNA11—melanoma	6.26e-07	9.39e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—FASN—melanoma	6.13e-07	9.19e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SLC5A5—melanoma	6.03e-07	9.04e-06	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—AKT1—melanoma	5.92e-07	8.88e-06	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HRAS—melanoma	5.83e-07	8.75e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—GNAQ—melanoma	5.82e-07	8.73e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CD44—melanoma	5.82e-07	8.73e-06	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—AKT1—melanoma	5.74e-07	8.61e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CB—melanoma	5.59e-07	8.38e-06	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IL6—melanoma	5.58e-07	8.37e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP1B1—melanoma	5.58e-07	8.37e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTGS2—melanoma	5.54e-07	8.3e-06	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—AKT1—melanoma	5.5e-07	8.25e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CG—melanoma	5.38e-07	8.06e-06	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CA—melanoma	5.28e-07	7.92e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PPARG—melanoma	5.19e-07	7.78e-06	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—AKT1—melanoma	5.15e-07	7.72e-06	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CA—melanoma	5.11e-07	7.66e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CG—melanoma	5.07e-07	7.6e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PPARG—melanoma	4.89e-07	7.33e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTEN—melanoma	4.83e-07	7.24e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CD—melanoma	4.73e-07	7.09e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—ALB—melanoma	4.67e-07	7e-06	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CA—melanoma	4.65e-07	6.97e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ABCB1—melanoma	4.6e-07	6.89e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CD—melanoma	4.45e-07	6.68e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ALB—melanoma	4.4e-07	6.59e-06	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AKT1—melanoma	4.31e-07	6.47e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PRKCA—melanoma	4.23e-07	6.34e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ERCC2—melanoma	4.2e-07	6.29e-06	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AKT1—melanoma	4.17e-07	6.26e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CB—melanoma	4.12e-07	6.18e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTGS2—melanoma	4.08e-07	6.12e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CB—melanoma	3.88e-07	5.82e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTGS2—melanoma	3.85e-07	5.77e-06	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AKT1—melanoma	3.8e-07	5.69e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTEN—melanoma	3.56e-07	5.34e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CA—melanoma	3.41e-07	5.11e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTEN—melanoma	3.36e-07	5.03e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CG—melanoma	3.31e-07	4.97e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPARG—melanoma	3.2e-07	4.79e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CD—melanoma	2.91e-07	4.37e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ALB—melanoma	2.88e-07	4.31e-06	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKT1—melanoma	2.78e-07	4.17e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CB—melanoma	2.54e-07	3.81e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTGS2—melanoma	2.52e-07	3.77e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CA—melanoma	2.51e-07	3.77e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CA—melanoma	2.37e-07	3.55e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTEN—melanoma	2.19e-07	3.29e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKT1—melanoma	2.05e-07	3.08e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKT1—melanoma	1.93e-07	2.9e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CA—melanoma	1.55e-07	2.32e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKT1—melanoma	1.26e-07	1.9e-06	CbGpPWpGaD
